# Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.

Study · id `cardio:ct-nct02681991` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02681991](<https://clinicaltrials.gov/study/NCT02681991>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02681991

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

## Technical summary

Registry record NCT02681991. Allocation not applicable; no masking; primary purpose treatment. Start 2016-01 (registry gives no type); primary completion 2016-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 110 participants (enrolled count; ClinicalTrials.gov record NCT02681991, source copy `cardio:ctgov-nct02681991-2017-07-06`, retrieved 2026-10-26)
- Start date: 2016-01 (registry gives no type) (ClinicalTrials.gov record NCT02681991, source copy `cardio:ctgov-nct02681991-2017-07-06`, retrieved 2026-10-26)
- Primary completion: 2016-09 (actual) (ClinicalTrials.gov record NCT02681991, source copy `cardio:ctgov-nct02681991-2017-07-06`, retrieved 2026-10-26)
- Completion: 2016-09 (actual) (ClinicalTrials.gov record NCT02681991, source copy `cardio:ctgov-nct02681991-2017-07-06`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02681991, source copy `cardio:ctgov-nct02681991-2017-07-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02681991-2017-07-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.
- Condition: Chronic Renal Failure
- Intervention (Drug): Renamezin capsule
- Lead sponsor: Daewon Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Daewon Pharmaceutical Co., Ltd. (`cardio:org-daewon-pharmaceutical-co-ltd`)

## Provenance

Content hash: b143fbed2e7174f47dc58e72bd3763f996407c5b5699827d3e57b6b9a897870a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
